Compare National Beverage Corp. (FIZZ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Johnson & Johnson — how do they compare? National Beverage Corp. trades at $30.56 (market cap $2.89B), while Johnson & Johnson trades at $260.28 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 216.6× National Beverage Corp.'s market cap, and Johnson & Johnson pays a 2.06% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | JNJ | |
|---|---|---|
Market Cap | $2.89B | $626.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $267.24 |
52-Week Low | $30.53 | $172.78 |
Enterprise Value | $2.60B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.45, down 1.9% on the day, with a bearish technical signal and recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margin improved to 15.56% in 2025. The company announced a special dividend of $3.25 per share, payable in July 2026, but faces declining LaCroix volumes and muted growth prospects.
The outlook is cautious due to stalled growth and bearish analyst sentiment, with 50% of coverage rating Sell. Risks include competitive pressures and weak volume trends, though the dividend provides some shareholder return. Upside appears limited without a clear catalyst for revenue acceleration.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
